B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies

ABSTRACT DNA sequence analysis recently identified the novel SARS-CoV-2 variant B.1.526 that is spreading at an alarming rate in the New York City area. Two versions of the variant were identified, both with the prevalent D614G mutation in the spike protein, together with four novel point mutations...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hao Zhou, Belinda M. Dcosta, Marie I. Samanovic, Mark J. Mulligan, Nathaniel R. Landau, Takuya Tada
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2021
Materias:	SARS-CoV-2 neutralization B.1.526 spike protein Pfizer BNT162b2 Moderna mRNA-1273 Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/d27f99fff4a1464d856ab08b87f4e537
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d27f99fff4a1464d856ab08b87f4e537
record_format	dspace
spelling	oai:doaj.org-article:d27f99fff4a1464d856ab08b87f4e5372021-11-10T18:37:52ZB.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies10.1128/mBio.01386-212150-7511https://doaj.org/article/d27f99fff4a1464d856ab08b87f4e5372021-08-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.01386-21https://doaj.org/toc/2150-7511ABSTRACT DNA sequence analysis recently identified the novel SARS-CoV-2 variant B.1.526 that is spreading at an alarming rate in the New York City area. Two versions of the variant were identified, both with the prevalent D614G mutation in the spike protein, together with four novel point mutations and with an E484K or S477N mutation in the receptor-binding domain, raising concerns of possible resistance to vaccine-elicited and therapeutic antibodies. We report that convalescent-phase sera and vaccine-elicited antibodies retain full neutralizing titer against the S477N B.1.526 variant and neutralize the E484K version with a modest 3.5-fold decrease in titer compared to D614G. The E484K version was neutralized with a 12-fold decrease in titer by the REGN10933 monoclonal antibody, but the combination cocktail with REGN10987 was fully active. The findings suggest that current vaccines and Regeneron therapeutic monoclonal antibodies will remain protective against the B.1.526 variants. The findings further support the value of widespread vaccination. IMPORTANCE A novel SARS-CoV-2 variant termed B.1.526 was recently identified in New York City and has been found to be spreading at an alarming rate. The variant has mutations in its spike protein that might allow it to escape neutralization by vaccine-elicited antibodies and might cause monoclonal antibody therapy for COVID-19 to be less successful. We report here that these fears are not substantiated; convalescent-phase sera and vaccine-elicited antibodies neutralized the B.1.526 variant. One of the Regeneron therapeutic monoclonal antibodies was less effective against the B.1.526 (E484K) variant but the two-antibody combination cocktail was fully active. The findings should assuage concerns that current vaccines will be ineffective against the B.1.526 (E484K) variant and suggest the importance of continued widespread vaccination.Hao ZhouBelinda M. DcostaMarie I. SamanovicMark J. MulliganNathaniel R. LandauTakuya TadaAmerican Society for MicrobiologyarticleSARS-CoV-2neutralizationB.1.526spike proteinPfizer BNT162b2Moderna mRNA-1273MicrobiologyQR1-502ENmBio, Vol 12, Iss 4 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 neutralization B.1.526 spike protein Pfizer BNT162b2 Moderna mRNA-1273 Microbiology QR1-502
spellingShingle	SARS-CoV-2 neutralization B.1.526 spike protein Pfizer BNT162b2 Moderna mRNA-1273 Microbiology QR1-502 Hao Zhou Belinda M. Dcosta Marie I. Samanovic Mark J. Mulligan Nathaniel R. Landau Takuya Tada B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
description	ABSTRACT DNA sequence analysis recently identified the novel SARS-CoV-2 variant B.1.526 that is spreading at an alarming rate in the New York City area. Two versions of the variant were identified, both with the prevalent D614G mutation in the spike protein, together with four novel point mutations and with an E484K or S477N mutation in the receptor-binding domain, raising concerns of possible resistance to vaccine-elicited and therapeutic antibodies. We report that convalescent-phase sera and vaccine-elicited antibodies retain full neutralizing titer against the S477N B.1.526 variant and neutralize the E484K version with a modest 3.5-fold decrease in titer compared to D614G. The E484K version was neutralized with a 12-fold decrease in titer by the REGN10933 monoclonal antibody, but the combination cocktail with REGN10987 was fully active. The findings suggest that current vaccines and Regeneron therapeutic monoclonal antibodies will remain protective against the B.1.526 variants. The findings further support the value of widespread vaccination. IMPORTANCE A novel SARS-CoV-2 variant termed B.1.526 was recently identified in New York City and has been found to be spreading at an alarming rate. The variant has mutations in its spike protein that might allow it to escape neutralization by vaccine-elicited antibodies and might cause monoclonal antibody therapy for COVID-19 to be less successful. We report here that these fears are not substantiated; convalescent-phase sera and vaccine-elicited antibodies neutralized the B.1.526 variant. One of the Regeneron therapeutic monoclonal antibodies was less effective against the B.1.526 (E484K) variant but the two-antibody combination cocktail was fully active. The findings should assuage concerns that current vaccines will be ineffective against the B.1.526 (E484K) variant and suggest the importance of continued widespread vaccination.
format	article
author	Hao Zhou Belinda M. Dcosta Marie I. Samanovic Mark J. Mulligan Nathaniel R. Landau Takuya Tada
author_facet	Hao Zhou Belinda M. Dcosta Marie I. Samanovic Mark J. Mulligan Nathaniel R. Landau Takuya Tada
author_sort	Hao Zhou
title	B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
title_short	B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
title_full	B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
title_fullStr	B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
title_full_unstemmed	B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
title_sort	b.1.526 sars-cov-2 variants identified in new york city are neutralized by vaccine-elicited and therapeutic monoclonal antibodies
publisher	American Society for Microbiology
publishDate	2021
url	https://doaj.org/article/d27f99fff4a1464d856ab08b87f4e537
work_keys_str_mv	AT haozhou b1526sarscov2variantsidentifiedinnewyorkcityareneutralizedbyvaccineelicitedandtherapeuticmonoclonalantibodies AT belindamdcosta b1526sarscov2variantsidentifiedinnewyorkcityareneutralizedbyvaccineelicitedandtherapeuticmonoclonalantibodies AT marieisamanovic b1526sarscov2variantsidentifiedinnewyorkcityareneutralizedbyvaccineelicitedandtherapeuticmonoclonalantibodies AT markjmulligan b1526sarscov2variantsidentifiedinnewyorkcityareneutralizedbyvaccineelicitedandtherapeuticmonoclonalantibodies AT nathanielrlandau b1526sarscov2variantsidentifiedinnewyorkcityareneutralizedbyvaccineelicitedandtherapeuticmonoclonalantibodies AT takuyatada b1526sarscov2variantsidentifiedinnewyorkcityareneutralizedbyvaccineelicitedandtherapeuticmonoclonalantibodies
_version_	1718439819731795968

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies

Ejemplares similares